Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Single-Use Technology: What’s to Come?
Bioprocessors Are Applying Single-Use Technology to Accomplish What Was Previously Impossible
- Single-use technology will continue to grow, but downstream processing remains the fly in the ointment for overall, or wider, adoption, says Surendra Balekai, senior global product manager-SUT, at Thermo Fisher Scientific. Protein expression rates are in the 3–4 g/L range at large scale with 5–8 g/L achievable at ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.